Activates Receptors
Activates melanocortin receptors in the brain that are involved in sexual desire and arousal.
$249.00
A prescription nasal spray designed to support sexual desire, arousal, and libido through central nervous system pathways.
Supports sexual desire: Bremelanotide activates central melanocortin pathways involved in sexual motivation and response.
Supports sexual arousal: Acts on nervous-system signaling associated with arousal and sexual response.
Works independently of blood-flow pathways: Unlike PDE5 inhibitors, PT-141 primarily targets central sexual-response pathways rather than vascular erectile function.
Convenient non-injectable delivery: Provides a nasal-spray option for clinician-directed bremelanotide treatment.
Blood pressure & cardiovascular health: Bremelanotide can temporarily increase blood pressure and reduce heart rate following administration. According to the supplied product information, PT-141 is not recommended for individuals with uncontrolled hypertension or cardiovascular conditions. Patients with high blood pressure, heart disease, previous heart attack or stroke, significant arrhythmias, or other cardiovascular conditions should discuss their history with their clinician.
Pregnancy & breastfeeding: Avoid use during pregnancy or breastfeeding. Patients who are pregnant, planning pregnancy, suspect they may be pregnant, or are breastfeeding should notify their clinician.
Nausea: Nausea is a recognized adverse effect of bremelanotide. Significant or persistent nausea or vomiting should be reported to the prescribing clinician.
Pigmentation changes: Bremelanotide has been associated with focal hyperpigmentation, including darkening of the face, gums, or breasts, particularly with repeated exposure. Some pigmentation changes may not completely resolve after discontinuation.
Nasal administration: Intranasal use may cause irritation, burning, congestion, runny nose, or nasal discomfort. Keep the spray tip clean and do not share the nasal spray with another person.
Potential side effects may include:
Individual response and tolerability may vary.
Bremelanotide activates melanocortin receptors in the nervous system. Its effects on sexual response are believed to involve central melanocortin signaling, particularly pathways associated with the MC4 receptor.
Sildenafil and tadalafil primarily enhance blood flow through the nitric oxide-cGMP pathway. PT-141 works differently, acting primarily through melanocortin receptors in the brain and targeting pathways associated with sexual desire and arousal.
Bremelanotide has been studied for its effects on sexual desire and libido. An FDA-approved injectable bremelanotide product exists for acquired, generalized HSDD in certain premenopausal women. This compounded nasal formulation is different and is not FDA-approved.
Compounded PT-141 may be incorporated into clinician-directed sexual-health protocols for men or women when a licensed clinician determines it is appropriate. FDA-approved bremelanotide, however, is approved for a specific form of HSDD in certain premenopausal women and is not approved to treat sexual dysfunction in men.
No. Bremelanotide is a peptide melanocortin receptor agonist, not testosterone, estrogen, progesterone, or another sex hormone. Its primary mechanism does not depend on directly increasing testosterone.
No. Sexual desire and arousal are influenced by neurological, hormonal, psychological, relational, and physical factors. PT-141 influences pathways associated with sexual response, but individual response varies.
Yes. Bremelanotide can cause temporary increases in blood pressure, making cardiovascular history and blood-pressure control important considerations before treatment.
No. This compounded PT-141 (Bremelanotide) Nasal Spray is not FDA-approved. The FDA-approved bremelanotide product is administered by subcutaneous injection and has a specific approved indication and dosing regimen. The compounded intranasal formulation should not be considered interchangeable with it.
PT-141 Nasal Spray is a compounded prescription formulation containing bremelanotide, a peptide that acts on melanocortin receptors in the central nervous system.
Unlike medications that primarily increase genital blood flow, PT-141 targets brain pathways involved in sexual desire, motivation, and arousal.
The nasal spray provides a non-injectable option for clinician-directed bremelanotide treatment.
This compounded PT-141 Nasal Spray is not FDA-approved and is not interchangeable with FDA-approved injectable bremelanotide.
All dosing should follow the instructions provided by the prescribing clinician.
PT-141 works differently from traditional erectile-dysfunction medications.
Activates melanocortin receptors in the brain that are involved in sexual desire and arousal.
Influences nerve signaling pathways associated with sexual motivation and response.
Works through the central nervous system rather than primarily increasing blood flow like traditional erectile dysfunction medications.
Acts through non-hormonal pathways without directly replacing or increasing testosterone, estrogen, or progesterone.
Low libido can have many potential contributors—including hormonal changes, medications, stress, sleep disruption, relationship factors, mood disorders, pain, and other medical or psychological factors. Persistent or distressing changes in sexual desire may benefit from broader evaluation.
All dosing should follow the instructions provided by the prescribing clinician.
PT-141 Nasal Spray contains bremelanotide, a melanocortin receptor agonist that acts primarily through central nervous system pathways involved in sexual motivation and arousal. Bremelanotide interacts with melanocortin receptors, particularly MC4R, and may influence neural signaling associated with sexual desire and response rather than acting primarily through vascular blood-flow pathways. This central mechanism distinguishes PT-141 from PDE5 inhibitors such as sildenafil and tadalafil, which primarily target nitric oxide–cGMP signaling and genital blood flow.
